Search Results

Klempner et al, 2 the patient was initiated on oral treatment with off-label dabrafenib, 150 mg twice daily, and trametinib, 2 mg daily. Restaging scans performed 8 weeks after initiation of dabrafenib/trametinib combination therapy demonstrated

inhibitor, was FDA-approved in May 2013 and seems to have equivalent activity in BRAF V600 -mutant melanoma. 6 Trametinib, an MEK inhibitor, also demonstrates a survival advantage in BRAF -mutant melanoma, with a response rate of 20% to 30%, and was also

dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3. Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to

the optic apparatus. Given the presence of somatic BRAF V600E mutation in the tumor, the patient elected to be treated with neoadjuvant combination BRAF/MEK inhibition with oral dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) in an

received an experimental targeted therapy of dabrafenib and trametinib (BRAF/MEK inhibitors). Overall, the high-grade glioma cohort received a median of one treatment (range 0–4) with a median follow up of 1.2 ± 0.9 years. Conclusion: Understanding the

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Phase II, Open-Label, 2-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anticancer Activity

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. A Phase II, Open-Label, 2-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anticancer Activity

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the

Trametinib (MEKi) in Patients With BRAF Mutation or BRAF Gene Fusion Defect in Thyroid Carcinoma Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD; Naifa L. Busaidy, MD; Lori Wirth, MD; Jonas DeSouza, MD; and

-institutional, randomized phase 2 trial studies how well dabrafenib works with or without trametinib for patients with metastatic thyroid carcinoma. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is